Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gressin, R.
Right arrow Articles by Sotto, J. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gressin, R.
Right arrow Articles by Sotto, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:S103-S106, 1997
© 1997 European Society for Medical Oncology

Treatment of mantle-cell lymphomas with the VAD +/– chiorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation

R. Gressin1, E. Legouffe2, D. Leroux1, M. C. Jacob1, P. Swiercz1, M. Peoch1, V. Capdevilla2, J. F. Rossi2, A. Thyss3 and J. J. Sotto1

1 Centre Hospitalier Universitaire Grenoble, France
2 Centre Hospitalier Universitaire Montpellier, France
3 CLCCA Lacassagne Nice, France

1Correspondence to: Dr. Rémy Gressin Service d'Hematologie Clinique Centre Hospitalier Universitaire de Grenoble BP 217 38043 Grenoble Cedex 09 France

Background MCL is a well-described clinicobiological entity that presents the worst prognosis of the small-cell lymphomas. No treatment is known as the reference treatment. On the basis, first, of cinicobiological similarities between MCLs and multiple myelomas and, second, of our experience of chiorambucil in high intermittent dose in MCLs, we have treated MCL with the VAD regimen both with and without chiorambucil.

Patients and methods Thirty disseminated MCL patients from three institutions, most in relapse (70%), were treated with the classical VAD regimen: 4 weeks VAD for 12 patients and VAD with 12 mg chiorambucil (d20–d29) for 5 weeks (VAD + C) for 18 patients. Five patients received complementary high-dose therapy (Alkeran or cyclophosphamide HD with TBI) and peripheral blood stem-cell transplantation.

Results Complete response was achieved in 43% of the patients in which 84.5% were treated by VAD + C. The median overall survival from the diagnosis was 52 months, and from the first VAD +/– C (OSvad) was 22.5 months, with a 20.5 month (0–75) median follow-up between diagnosis and the first VAD +/– C. The OSvad was significantly better for patients with fewer than two prognostic factors (ECOG, lymphocytosis, blastic variant, LDH level, and Ki-67 score). Four of five patients treated with HDT and PBSCT were alive in CR 12.5 months (7–22) after the first VAD +/– C regimen.

Conclusions The VAD regimen appears effective in disseminated MCL patients and even better when associated with chlorambucil. HDT and PBSCT appear promising in younger patients in CR before HDT. A multicenter prospective study is in preparation to confirm these encouraging results.

mantle-cell lymphoma, non-Hodgkin's lymphoma, VAD regimen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.